TSTickerStarGet alerts
Company alerts/CODX
CODX company alerts

CODX updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for CODX. Subscribe to CODX alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Subscribe for CODX alertsView companies
Official-source feed

Recent CODX alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

Debt offeringSEC filing

Co-Diagnostics special meeting covers financing-related issuance, equity dilution and reverse split

Co-Diagnostics will hold a court-ordered special meeting on November 13, 2026 at 7:30 a.m. Mountain Time, with an October 22, 2026 record date and a one-third quorum. The nine proposals cover five director re-elections, an equity-plan share increase, say-on-pay, auditor ratification, a permanent one-third quorum, exercise of 3,404,724 warrants, note-conversion share issuance, a reverse-split authorization and adjournment. The board unanimously recommends voting FOR all nine proposals.

Read source-backed brief
Debt offeringSEC filing

Co-Diagnostics files preliminary proxy for court-ordered special meeting covering director election, 2025 plan share increase, Nasdaq warrant/conversion approvals, and reverse stock split

Co-Diagnostics filed a preliminary proxy statement for a court-ordered 2026 Special Meeting of Shareholders pursuant to an October 15, 2026 order of the Business and Chancery Court of Utah under Utah Code § 16-10a-703, reducing the meeting quorum to one-third of votes entitled to be cast. The proxy covers nine proposals, including the election of five directors, a 2,000,000-share increase under the 2025 Equity Incentive Plan, say-on-pay, ratification of Tanner LLC as auditor for FY2026, an Articles amendment to...

Read source-backed brief
Company updateOfficial company source

Co-Diagnostics 8-K: 2026 annual meeting adjourned without quorum; company to seek future special meeting

Co-Diagnostics, Inc. filed a Form 8-K on October 15, 2026 disclosing that its Annual Meeting of Stockholders, originally convened on September 3, 2026, failed to achieve a quorum on each of four attempts (September 3, September 24, September 30, and October 14, 2026) and was not further adjourned. No proposals were voted on at the Annual Meeting. The Company stated it currently intends to seek stockholder approval of the proposals that were to be considered at the Annual Meeting at a special meeting of stockhold...

Read source-backed brief
Debt offeringSEC filing

Co-Diagnostics enters into $3.1 million senior secured convertible loan with J.J. Astor & Co.

On October 9, 2026, Co-Diagnostics entered into a Loan Agreement with J.J. Astor & Co. providing up to $3.1 million in senior secured convertible loan funding across two tranches, with $2.1 million funded at closing and an additional $1.0 million available after 60 days, subject to conditions. The Initial Note has a $2.835 million Original Principal Amount (1.35x factor) and pays in 30 weekly installments of $94,500, maturing May 7, 2027, and is convertible at the greater of 90% of the lowest 10-day VWAP or the...

Read source-backed brief